Many classified malignancies, including the most common ovarian cancer, which remains undetectable until it has metastasized, sadly worsen the condition, subsequently resulting in death due to a lack of medical support. Protheragen has several ovarian cancer animal models, which will help them bridge the gap between their theoretical knowledge and practical knowledge that has clinical implementations. Through our knowledge and application, certain animal models are developed, which are not only research instruments but core frameworks that induce new, insightful outcomes.
Overview of Ovarian Cancer Animal Models
Ovarian cancer animal models are experimentally induced or genetically modified animals that develop tumors resembling human ovarian cancer. These models can be generated using various techniques, including chemical carcinogenesis, transplantation of human or mouse ovarian cancer cell lines, and genetic engineering to introduce specific mutations associated with ovarian cancer. The primary goal of these models is to replicate the key features of human ovarian cancer, such as tumor growth patterns, metastatic behavior, and response to treatments, thereby providing a platform for preclinical research.
Fig.1 Overview of high-grade serous ovarian cancer (HGSOC) and its animal models. (Maniati E.,
et al., 2020)
Types of Ovarian Cancer Animal Models
Spontaneous Models
Spontaneous models involve animals that develop ovarian tumors naturally without genetic manipulation or transplantation. These models are rare and often limited by low incidence rates and long development times. For instance, certain strains of mice and rats, such as the C3HeB/Fe and C3HeB/De strains, develop spontaneous granulosa cell tumors and tubular adenomas. However, the low frequency and extended time required for tumor development make these models less feasible for experimental studies.
Xenograft Models
Xenograft models involve transplanting human ovarian cancer cells into immunodeficient mice. These models are widely used for studying tumor growth, metastasis, and therapeutic efficacy. For example, the injection of ovarian cancer cells into the intra-bursal space of mice results in tumor formation that closely mimics the physiological environment of ovarian cancer. While these models are valuable for studying specific aspects of ovarian cancer, they may not fully represent the human immune response due to the absence of a functional immune system in immunodeficient mice.
Genetically Engineered Mouse Models (GEMMs)
GEMMs are created by introducing specific genetic modifications to mice, allowing researchers to study the effects of particular mutations on ovarian cancer development. These models can be designed to express oncogenes or knock out tumor suppressor genes, providing insights into the genetic basis of ovarian cancer. For instance, models using the MISIIR promoter to drive the expression of SV40 TAg in the ovarian surface epithelium have successfully developed ovarian carcinomas with metastatic spread, closely resembling human ovarian cancer.
Our Services
Protheragen's ovarian cancer animal model development services provide a comprehensive solution for researchers seeking to advance their understanding of ovarian cancer and develop novel therapeutics. Our models are designed to meet regulatory standards, facilitating the transition from preclinical to human studies.
| Disease |
Cell Line |
Detailed Description |
Background |
Organism |
Sales Status |
| Ovarian Cancer |
CHO-K1-Luc |
Luciferase-labeled CHO-K1-Luc cell line |
- |
Mouse |
Construction |
| Ovarian Cancer |
HO-8910PM-Luc |
Luciferase-labeled human HO-8910PM cell. |
- |
Human |
Construction |
| Ovarian Cancer |
OVCAR-3-Luc |
Luciferase-labeled human OVCAR-3 cell. |
- |
Human |
Construction |
| Ovarian Cancer |
SKOV-3-Luc |
Luciferase-labeled SKOV-3 cell line |
- |
Human |
Construction |
| Ovarian Cancer |
A2780 |
The A2780 human ovarian cancer cell line was established from tumor tissue from an untreated patient with ovarian endometroid adenocarcinoma. |
M-NSG |
Human |
Validation of tumorigenic capacity completed |
| Ovarian Cancer |
CHO-K1 |
Hamster ovary cells |
- |
Mouse |
Validation of tumorigenic capacity |
| Ovarian Cancer |
ES-2 |
Human ovarian clear cell Carcinoma |
- |
Human |
Validation of tumorigenic capacity |
| Ovarian Cancer |
HO-8910PM |
Human ovarian epithelial carcinoma cell line |
- |
Human |
Validation of tumorigenic capacity |
| Ovarian Cancer |
ID8 |
mouse ovarian epithelial cancer cell line |
- |
Mouse |
Validation of tumorigenic capacity |
| Ovarian Cancer |
NIH:OVCAR-3 [OVCAR3] |
OVCAR3 are epithelial cells that were isolated in 1982 from the malignant ascites of a patient with progressive adenocarcinoma of the ovary. |
M-NSG |
Human |
Validation of tumorigenic capacity completed |
| Ovarian Cancer |
OV90 |
OV-90 is an epithelial-like cell isolated from the ovary of a female patient with malignant papillary serous adenocarcinoma. |
- |
Human |
Validation of tumorigenic capacity completed |
| Ovarian Cancer |
SK-OV-3 [SKOV-3; SKOV3] |
SK-OV-3 is a cell line with epithelial morphology that was isolated from the ovary of a 64-year-old, White female with ovarian adenocarcinoma. |
Balb/C nude |
Human |
Validation of tumorigenic capacity completed |
| Model Types |
Regular Transgenic Mice |
| Model Name |
R26-CAG-LSL-hPIK3CA*H1047R-IRES-Luc-2A-tdTomato Mice |
| Also Known As |
C57BL/6-Gt(ROSA)26Sorem1(CAG-LSL- |
| Detailed Description |
These mice harbor a CAG-LSL-PIK3CA (H1047R)-IRES-luciferase-2A-tdTomato cassette in the Rosa26 locus generated by homologous recombination. |
| NCBI ID |
14910 |
| MGI ID |
104735 |
| Gene Alias |
R26, ROSA26, AV258896, Gtrgeo26, Gtrosa26, Thumpd3as1 |
| Sales Status |
Repository live |
| Applications & Therapeutic Areas |
Breast Cancer; Cloves Syndrome; Ovarian Cancer; Brain Glioma |
| Ensembl ID |
ENSMUSG00000086429 |
| Pubmed |
Gt(ROSA)26Sor |
Humanized Mouse Models
Humanized mouse models incorporate human immune cells into mice, enabling the study of immune interactions with ovarian cancer. These models are essential for evaluating immunotherapies and understanding the role of the immune system in cancer progression. Protheragen has developed advanced humanized mouse models that support the engraftment of human immune cells and ovarian cancer cells, providing a powerful platform for preclinical studies.
Case Study
High-Grade Serous Ovarian Cancer (HGSOC) Orthotopic Mouse Model
At Protheragen, we have developed a high-grade serous ovarian cancer (HGSOC) orthotopic mouse model using the immunocompetent C57BL/6J strain. This model is constructed by injecting genetically engineered HGSOC cell lines, which harbor mutations commonly found in human HGSOC, such as Brca2, Trp53, and Pten, into the ovarian bursa of female mice. This method ensures that the tumors develop in the correct anatomical location, closely mimicking the human disease. The model supports the study of tumor growth, metastasis, and immune interactions, making it a powerful tool for preclinical research and therapeutic evaluation.
Fig 2. Changes in tumor volume and weight after injection of genetically engineered HGSOC cell lines.
Protheragen's team of experts works closely with clients to design and develop animal models that accurately reflect the genetic and phenotypic characteristics of ovarian cancer. We offer a range of options, from spontaneous and xenograft models to genetically engineered and humanized models, ensuring that each model is optimized for the intended research application. If you are interested in our services, please feel free to contact us.
References
- Maniati, Eleni, et al. "Mouse ovarian cancer models recapitulate the human tumor microenvironment and patient response to treatment." Cell reports 30.2 (2020): 525-540.
- Magnotti, Elizabeth, and Wayne A. Marasco. "The latest animal models of ovarian cancer for novel drug discovery." Expert opinion on drug discovery 13.3 (2018): 249-257.
- Vanderhyden, Barbara C., Tanya J. Shaw, and Jean-François Ethier. "Animal models of ovarian cancer." Reproductive Biology and Endocrinology 1.1 (2003): 67.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
